Drug Profile
CKD 504
Alternative Names: CKD-504Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Antidementias
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Huntington's-disease in South Korea (PO)
- 17 Aug 2021 CKD 504 is still in phase-I trials for Huntington's-disease in South Korea (PO) (Chong Kun Dang Pharmaceutical pipeline, August 2021)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Huntington's-disease in South Korea (PO)